Home / Therapeutic Areas / Infectious Disease & Vaccines
Infectious Disease & Vaccines
Our experts help you fight emerging and re-emerging diseases by rigorously studying the effectiveness of your therapies and vaccines.
Home / Therapeutic Areas / Infectious Disease & Vaccines
Our experts help you fight emerging and re-emerging diseases by rigorously studying the effectiveness of your therapies and vaccines.
Access our global infectious disease and vaccine experience to fight emerging and re-emerging diseases.
Sigma-Chi is ready to partner with you to conduct trials for infectious diseases caused by viruses, bacteria, fungi, or parasites. We’ve been part of the effort against COVID-19, and our extensive experience provides a significant advantage in proven strategic planning, regulatory guidance, and successful clinical trial execution.
It’s important to choose a team that has the right kind of therapeutic experience for your clinical trial. Sigma-Chi’s therapeutically aligned, specialized staff have a broad range of expertise in infectious disease and vaccine clinical development and regulations from the U.S., EU, and beyond.
Our vaccines development experts have extensive experience designing, implementing, and executing clinical trials involving live attenuated, inactivated, subunit, toxoid, mRNA, and viral vector vaccines for infectious diseases, allergies, immunotherapies, and oncology indications. These include COVID-19, hepatitis B & C, grass, birch, and dust mite allergies, cervical cancer, and melanoma.
Data-driven, risk-based monitoring solutions, including centralized monitoring, are designed specifically to manage large data volumes upon enrollment of vaccine trials, while ensuring data integrity in remote settings.
Natural selection of pathogens, diversity of trial participants, and timing are all important site-selection criteria for infectious disease clinical trials. Our global reach, including industry-leading Central and Eastern Europe specialization, provides access to patient populations, site networks, and academic institutions, focused on meeting and exceeding your enrollment goals.
Sigma-Chi’s teams have deep expertise in supporting studies in an ICU/critical care setting and navigating the common challenges encountered in this complex environment. That knowledge enables us to provide proactive and insightful CRO services based on proven strategies for indications from pneumonia to COVID-19.
Whether your new product is a drug, vaccine, biologic, GMO, cell and gene therapy, device, or a combination product, we understand the nuances of regulatory requirements and have the resources and proven expertise to address your specific needs.
Sigma-Chi stands with the global community in the fight against COVID-19. No other disease in recent history has captured the world like Coronavirus. We are poised to help pharmaceutical and biotech companies by rapidly deploying their clinical trials in the search for vaccines and therapies to fight infectious disease.
We understand that drug development partners with medical countermeasures (MCM) expertise are crucial in bringing vaccines and treatments to the front lines of the COVID-19 battle. As an MCM-capable CRO, Sigma-Chi has the full capabilities to support your initiative.
Your connection to this website is encrypted. You can check its security status at any time with these free, independent services:
GoogleGoogle Safe BrowsingMalware, phishing and unsafe contentCheck → SucuriSucuri SiteCheckMalware and blacklist scanScan → 🔒 SSLSSL certificateHTTPS encryption report by SSL LabsView →We protect your data as described in our Privacy Policy.